VAXART, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.916 USD | +5.93% |
|
+22.56% | +56.20% |
| May. 13 | Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
| May. 13 | Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Vaxart Business Update a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.8647
USD
Average target price
5
USD
Spread / Average Target
+478.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.20% | 153M | |
| +7.25% | 111B | |
| +10.33% | 106B | |
| -12.46% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -9.22% | 16.81B | |
| +38.77% | 12.54B | |
| -24.83% | 8.09B |
- Stock Market
- Equities
- VXRT Stock
- News Vaxart, Inc.
- Transcript : Vaxart, Inc., 2022 Earnings Call, Mar 15, 2023